台灣臨床試驗主持人資料庫|TPIDB

2015-11-01 - 2025-08-29

Phase III

Completed

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

Nivolumab

Participate Sites
5Sites

Terminated5Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2019-01-01 - 2025-12-31

Phase I

Completed

Phase 1-2 Study of ADI PEG 20 plus FOLFOX in Subjects with Advanced Gastrointestinal Malignancies Focusing on Hepatocellular Carcinoma (HCC)

Condition/Disease

Hepatocellular carcinoma
Test Drug

ADI-PEG20

Participate Sites
13Sites

Terminated12Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2016-01-01 - 2019-08-31

Phase III

An international, randomised, multi-centre, active controlled, open-label Phase III study evaluating the efficacy of in patients with T790M-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease progressed on one epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment

Condition/Disease

Non-Small Cell Lung Cancer (NSCLC)
Test Drug

AZD9291

Participate Sites
9Sites

Terminated8Sites

楊政達

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

鍾飲文

Kaohsiung Municipal Gangshan Hospital

未分科

2017-02-01 - 2023-02-28

Phase III

A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Condition/Disease

Renal Cell Carcinoma
Test Drug

Atezolizumab

Participate Sites
6Sites

Terminated5Sites

莊正鏗

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-07-01 - 2022-07-30

Phase III

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease

Condition/Disease

Mild Alzheimer's Disease
Test Drug

Crenezumab

Participate Sites
7Sites

Terminated6Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

胡朝榮

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Neurology

2018-03-01 - 2023-12-31

Phase III

A Phase III, Open-Label, Randomized Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma

Condition/Disease

Hepatocellular Carcinoma (HCC)
Test Drug

Atezolizumab; Bevacizumab; Sorafenib

Participate Sites
5Sites

Terminated5Sites

楊再勝

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅

Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-04-10 - 2019-06-30

Phase III

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF MPDL3280A (AntiPD-L1 ANTIBODY) IN COMBINATION WITH BEVACIZUMAB VERSUS SUNITINIB IN PATIENTS WITH UNTREATED ADVANCED RENAL CELL CARCINOMA

Condition/Disease

UNTREATED ADVANCED RENAL CELL CARCINOMA
Test Drug

Atezolizumab

Participate Sites
3Sites

Terminated3Sites

莊正鏗

Linkou Chang Gung Medical Foundation

Division of General Surgery

2017-06-01 - 2018-06-01

Phase I

Condition/Disease
Test Drug

Participate Sites
1Sites

Terminated1Sites

黃錦章

Linkou Chang Gung Medical Foundation

Division of Neurology

2017-10-01 - 2020-09-30

Phase II/III

A Two-part, Open-label, Randomized, Phase 2/3 Study of Dinutuximab and Irinotecan Versus Irinotecan for Second Line Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer

Condition/Disease

Small Cell Lung Cancer
Test Drug

Unituxin®

Participate Sites
5Sites

Terminated5Sites

劉劍英

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2017-12-01 - 2020-08-05

Others

A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of 24 Weeks of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)ide Analog in Subjects With Chronic Hepatitis B Virus Infection

Condition/Disease

Chronic Hepatitis B Virus Infection
Test Drug

JNJ-56136379

Participate Sites
4Sites

Terminated4Sites

葉昭廷

Linkou Chang Gung Medical Foundation

Digestive System Department

Search Result

List